Drug intelligence / Profile preview

QPCF-NPs

Development stage: Preclinical
Lead developer: Kumaun University
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules
Administration: Subcutaneous

Overview

**QPCF-NPs** are an experimental, folic acid-chitosan-coated poly(lactic-co-glycolic acid) nanoparticle formulation encapsulating **quercetin**. The formulation was designed to provide sustained quercetin release and improve tumor-directed delivery for hepatocellular carcinoma. In reported HepG2-cell and carcinogen-induced rat hepatocellular carcinoma studies, subcutaneously administered QPCF-NPs showed greater cytotoxicity and antitumor-associated biochemical, oxidative-stress, inflammatory, and caspase-3 changes than unformulated quercetin. This is a preclinical academic nanomedicine formulation and is not an approved medicine.

Other names: chitosan-folic acid-coated quercetin-loaded PLGA nanoparticlesQPCF-NPs

Targets

FOLR1 (FRα)

Beyond the preview

Go deeper on QPCF-NPs.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QPCF-NPs.

Explore the full profile